Bibliography, by cancer type
If you would like a full-text of any of these articles please let me know and I will request it from the authors!
Adenoid Cystic Sarcoma (click for more info)
ATRT
Article: Preclinical High-Dose Acetaminophen With N-Acetylcysteine Rescue Enhances the Efficacy of Cisplatin Chemotherapy in Atypical Teratoid Rhabdoid Tumors
https://www.ncbi.nlm.nih.gov/pubmed/23956023
Basosquamous Cell Carcinoma (click for more info)
Breast Cancer (click here for more info)
Study: The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women.
Summary: "Flaxseed supplementation significantly increased the urinary 2:16alpha-OHE1 ratio (P = 0.034), but wheat bran had no effect. These results suggest that flaxseed may be chemoprotective in premenopausal women."
https://www.ncbi.nlm.nih.gov/pubmed/10919743
Study - Oncolytic Vaccinia Virus GLV-1h68 Strain Shows Enhanced Replication in Human Breast Cancer Stem-Like Cells in Comparison to Breast Cancer Cells
"Conclusions: Taken together, our findings indicate that GLV-1h68 efficiently replicates and kills cancer stem-like cells. Thus, GLV-1h68 may become a promising agent for eradicating both primary and metastatic tumors, especially tumors harboring cancer stem-like cells that are resistant to chemo and/or radiotherapy and may be responsible for recurrence of tumors."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478222/pdf/1479-5876-10-167.pdf
Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells.
Note* "This work was supported by a sponsored research grant from EcoNugenics."
https://www.ncbi.nlm.nih.gov/pubmed/22532035 - full text: https://journals.sagepub.com/doi/pdf/10.1177/1534735412442369
Zantac
From Courtney Collins, part of the Community Outreach team for Florin|Roebig:
Our firm has a long history of promoting and educating the public on issues of social justice and public safety. Because of our passion for community involvement, we wanted to use our experience and gathered knowledge to create informational resources.
Late 2019, FDA released a statement alerting patients and healthcare providers of a safety concern regarding the drug, ranitidine, commonly bought under the brand name, Zantac. The test findings demonstrate toxic levels of a carcinogenic ingredient known as NDMA. Many claim these drug makers marketed and sold drugs contaminated with toxic amounts of NDMA, without disclosing the health risks, such as cancer-causing effects, to the government or the public.
Consumers and their loved ones are understandably concerned about the recent statements. It's important to make this information much more accessible than it's been in the past.
In this guide, "The Link Between Zantac and Breast Cancer", we touch on points such as:
-
Can Zantac Cause Breast Cancer?
-
About NDMA: The Cancerous Chemical in Zantac.
-
What To Do If You've Developed Cancer After Taking Zantac?
-
& much more.
Triple Negative Breast Cancer
Study - Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.
https://www.ncbi.nlm.nih.gov/pubmed/?term=selective+nontoxic+cb2+cannabinoid
Review - Future Aspects for Cannabinoids in Breast Cancer Therapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479799/pdf/ijms-20-01673.pdf
"(S)-HPLA farnesyl amide was active to triple-negative MDA-MB-231 breast cancer cells (IC50 = 27 μM) and 10-fold less toxic to Detroit-551 normal cells."
https://pubmed.ncbi.nlm.nih.gov/26499209/
"Our results suggest that sulforaphane may control the malignant proliferation of CSCs in TNBC via Cripto-mediated pathway by either suppressing its expression and/or by inhibiting Cripto/Alk4 protein complex formation. Thus, the use of sulforaphane for chemoprevention of TNBC is plausible and warrants further clinical evaluation."
Cell lines: https://www.atcc.org/support/faqs/1f180/Triple+negative+breast+cell+lines-1181.aspx#targetText=Do%20you%20have%20triple%20negative,most%20hormone%2Dbased%20treatments%20inadequate
Chondrosarcoma
Study: Advances in immune checkpoint inhibitors for bone sarcoma therapy (J Bone Oncology, April 2019)
https://www.sciencedirect.com/science/article/pii/S2212137418303269?via%3Dihub
Immunotherapy is in the early stages of research through clinical trials. Results are hoped to be published soon on the findings as surgery, chemotherapy and radiation have not been proven effective in this type of cancer.
Colon Cancer
Study - Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses.
The mistletoe extract administration increased production of multiple immune cells, from both the innate and adaptive immune systems, and delayed colon cancer growth in the mice.
https://www.ncbi.nlm.nih.gov/pubmed/18785279 (Full text available at https://www.wjgnet.com/1007-9327/full/v14/i34/5274.htm)
Study - Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer
https://www.researchgate.net/publication/333052937_Cannabidiol_Enhances_the_Therapeutic_Effects_of_TRAIL_by_Upregulating_DR5_in_Colorectal_Cancer
"Cannabidiol, a major non-psychotomimetic compound derived from Cannabis sativa, is a potential therapeutic agent for a variety of diseases such as inflammatory diseases, chronic neurodegenerative diseases, and cancers. Here, we found that the combination of cannabidiol and TNF-related apoptosis-inducing ligand (TRAIL) produces synergistic antitumor effects in vitro. However, this synergistic effect was not observed in normal colonic cells. The levels of ER stress-related proteins, including C/EBP homologous protein (CHOP) and phosphorylated protein kinase RNA-like ER kinase (PERK) were increased in treatment of cannabidiol. Cannabidiol enhanced significantly DR5 expression by ER stress. Knockdown of DR5 decreased the combined effect of cannabidiol and TRAIL. Additionally, the combination of TRAIL and cannabidiol decreased tumor growth in xenograft models. Our studies demonstrate that cannabidiol enhances TRAIL-induced apoptosis by upregulating DR5 and suggests that cannabidiol is a novel agent for increasing sensitivity to TRAIL."
Study - Growth Inhibition of Different Human Colorectal Cancer Xenografts After a Single Intravenous Injection of Oncolytic Vaccinia Virus GLV-1h68
https://pubmed.ncbi.nlm.nih.gov/23531320-growth-inhibition-of-different-human-colorectal-cancer-xenografts-after-a-single-intravenous-injection-of-oncolytic-vaccinia-virus-glv-1h68/
Study - Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic Implications
https://www.liebertpub.com/doi/full/10.1089/biores.2016.0028
Abstract: Genetic, environmental, and dietary factors have been found to influence the development and progression of colorectal cancer (CRC). More recently, accumulating evidence associates the intestinal microbiota with the initiation and progression of this disease. While studies have shown that individuals with CRC display alterations in gut bacterial composition, it remains somewhat unclear whether such differences drive cancer development or whether they are a response to tumorigenesis. In this review, the authors assess new evidence linking the community structure or specific bacterial factors of the intestinal microbiota to CRC development and progression, with insights into therapeutic implications.
COVID-19 (Click here for more info)
Glioblastoma
Article - Glioblastoma linked to Lyme Disease
Naturopathic doctor, Dr. Darvish hypothesized that glioblastoma was caused by Borrelia bergdorferi, the organism that causes Lyme disease, after each of her glioblastoma patients experienced tumor shrinkage following a holistic, non-antibiotic treatment program for Lyme disease. Biopsies of 5 patients evaluated by a neuropathologist each tested positive for Borrelia bergdorferi!!
Leukemia
Spontaneous remissions are often associated with infections! (See next 3 articles below.)
"Spontaneous remission (SR) of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the absence of disease-modifying therapy is rare.1-5 One review identified 46 cases of AML SRs published between 1950 and 2014.6 Infections preceded >70% of SRs, leading to the hypothesis that the immunostimulatory effect of severe infections may occasionally induce immune-mediated blast clearance. Others suggested that donor lymphocytes from nonirradiated blood products may induce SR through allo-immune effects.7-9 However, infections and transfusion-dependent cytopenias are common in AML patients, and thus their association with SRs may be coincidental.4 SR has also been documented in MDS,10 particularly in children and young adults with abnormalities of chromosome 7.11-15"
Case Report - Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
"We describe a case of late relapse of Philadelphia-like acute lymphoblastic leukemia. The patient relapsed several years from diagnosis and responded to second salvage treatment. The case highlights the open questions regarding management of Philadelphia-like acute lymphoblastic leukemia."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360594/
A man in his late 50s had lumbago and thrombocytopenia. He was diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph plus ALL). Remission induction chemotherapy was initiated with JALSG Ph plus ALL 208 protocol, but cerebral infarction in the right occipital lobe developed on day 2 and, to make matters worse, was accompanied by hemorrhagic cerebral infarction in the left occipital lobe on day 9. We decided that chemotherapy with multiple drugs was difficult to continue, and it was stopped. After improvement of the general condition, dasatinib therapy was started on day 52. After about 5 months, Ph plus ALL relapsed. Although mild disorientation and visual field defects remained due to old cerebral infarction, organ function was maintained, and patient performance status(PS)was classified as 1. Introduction of ponatinib was considered feasible, and ponatinib was started from a dose of 15mg/day to prevent the occurrence of vaso- occlusive adverse events. It was gradually increased to 30mg /day and continued about 4 months without recurrence of cerebral infarction. Complete molecular response was achieved with ponatinib therapy. It was suggested that, in patients with Ph plus ALL with a history of cerebral infarction, ponatinib could be a treatment option under careful risk management.
https://pubmed.ncbi.nlm.nih.gov/31748496/
"A 59-year-old female was diagnosed as [invasive] pulmonary aspergillosis (IPA) while remission induction therapy** for Philadelphia chromosome-positive acute lymphoblastic leukemia. Liposomal amphotericin B [antifungal medication] improved the fungal serodiagnostic markers, however, the IPA worsened. She also developed an Aspergillus brain abscess, which, while being undetectable on CT, was detected as multiple nodular lesions by MRI. A definitive diagnosis was made by polymerase chain reaction (PCR) of brain biopsy specimens. Voriconazole (VRCZ) was effective, and cord blood transplantation was performed. She has received VRCZ for a long time. There are no relapse of either the IPA or the Aspergillus brain abscess."
*Dasatinib is a kinase inhibitor. "It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells."
https://medlineplus.gov/druginfo/meds/a607063.html
**Remission induction therapy: "Induction treatment is also called remission induction therapy. The goal of induction treatment for acute myelogenous leukemia (AML) is to clear the blood and bone marrow of immature blood cells (called blast cells, or blasts) and bring about a complete remission, or complete response. This treatment is usually given over 1 week."
https://www.cancer.ca/en/cancer-information/cancer-type/leukemia-acute-myelogenous-aml/treatment/induction/?region=on
"Patient concerns: A 59-year-old man who was newly diagnosed PH ALL with 93% blast cells and a t (9, 22) karyotype. But the patient also suffered from pulmonary infection, including fever and dyspnea....
Diagnoses: The patient was newly diagnosed with Ph ALL with pulmonary infection.
Interventions: The patient received oral dasatinib monotherapy (100 mg qd) for 28 days as induction therapy.
Outcomes: The patient reached complete remission with negative minimal residual disease detected by real-time quantitative polymerase chain reaction after induction therapy for 28 days."
https://pubmed.ncbi.nlm.nih.gov/30235679/
Case Report - Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide
A 54-year-old Chinese male patient who complained of chest pain and fatigue for 20 days. Bone marrow aspirate examination revealed hypercellularity with 70% blast cells... Diagnosis: Philadelphia chromosome-positive mixed phenotype acute leukemia.
Interventions: After relapsed from routine chemotherapy plus imatinib, the therapy was switched to oral therapy with nilotinib and lenalidomide due to his feeble condition. Outcomes:He successfully achieved long survival after oral therapy with nilotinib and lenalidomide.
Lung Cancer
Blue light therapy as a potential sensitizer in lung cancer cells: https://pubmed.ncbi.nlm.nih.gov/34144355/ It's both anti-cancer and antibacterial. Coincidence?
Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Lung Cancer
"Higher insulin levels and insulin resistance were associated with increased lung cancer risk. Although smoking cessation is the best method of lung cancer prevention, other lifestyle changes that affect insulin concentrations and sensitivity may reduce lung cancer risk."
General Resource - Lung Cancer Center
Mesothelioma
https://mesothelioma.net/about-us-contact/
Mesothelioma Hub - https://www.mesotheliomahub.com/
For information on potential lawsuits and conventional treatment options.
Mesothelioma Justice Center - https://www.asbestos.net/mesothelioma/
Information on mesothelioma, legal support for veterans.
Mesothelioma Veterans Center - https://www.mesotheliomaveterans.org/mesothelioma/
Help for veterans suffering with mesothelioma.
Multiple Myeloma (click for more info)
Fruits from the Arctium lappa L. plant have been shown to be cytotoxic to multiple myeloma cells!!
Study - Arctiin Is a Pharmacological Inhibitor of STAT3 Phosphorylation at Tyrosine 705 Residue and Potentiates Bortezomib-Induced Apoptotic and Anti-Angiogenic Effects in Human Multiple Myeloma Cells
"Arctiin exerted cytotoxicity in MM cells...[and] down-modulated diverse oncogenic gene products regulated by STAT3, although the induction of apoptosis by arctiin was abrogated upon transfection with pMXs-STAT3C in mouse embryonic fibroblast (MEF) cells. Arctiin also potentiated bortezomib-induced antitumor effects in U266 cells."
This study showed a correlation between a higher intake of fruit and a lower risk for MM. It would then make sense that fruit could help with the disease regression!
Study - Dietary Intake Is Associated With Risk of Multiple Myeloma and Its Precursor Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211667/
Ovarian Cancer (click for more info)
Articles on hyperthermia for ovarian cancer (one was done at MDACC):
Study, conducted in China - The efficacy of radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer
"Conclusion. Radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer has significantly improved the tumor remission rate, ascite control and CA125 levels, and substantially
reduced the gastrointestinal reaction and bone marrow suppression rate, which is worthy of intensive clinical
application."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984478/pdf/med-13-083.pdf
Study, conducted at MD Anderson - Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123842/pdf/nihms823441.pdf
Study - Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663976/pdf/fonc-09-00660.pdf
Article - Spontaneous regression of pancreatic cancer: Real or a misdiagnosis? (click to access)
Study - The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817443/pdf/oncotarget-10-6269.pdf
Prostate Cancer
Article - Thermal ablation and high-temperature thermal therapy: Overview of technology and clinical implementation
https://www.tandfonline.com/doi/pdf/10.1080/02656730500271692?needAccess=true
Article - Treating Prostate Cancer (Dr. Michael Gregor)
https://nutritionfacts.org/audio/treating-prostate-cancer/
Review - Dietary Intervention in the Management of Prostate Cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659357/pdf/nihms93676.pdf
"To date, the strongest evidence regarding diet and CaP relates to energy balance. Urologists aspiring to best clinical practice should encourage their patients to achieve a healthful body weight through regular exercise and a healthful plant-based diet rich in fruits, vegetables and whole grains."
Study - INTENSIVE LIFESTYLE CHANGES MAY AFFECT THE PROGRESSION OF PROSTATE CANCER
https://www.ornish.com/wp-content/uploads/Intensive_Lifestyle_Changes_and_Prostate_Cancer.pdf
Prostate cancer growth markers (PSA, LNCaP cells) decreased 4% and 8% respectively after dietary intervention in men with prostate cancer.
Sarcoma
Study - Isolated Limb Perfusion With Biochemotherapy and Oncolytic Virotherapy Combines With Radiotherapy and Surgery to Overcome Treatment Resistance in an Animal Model of Extremity Soft Tissue Sarcoma
"In vitro, the combination of radiation with an oncolytic vaccinia virus (GLV-1h68) and melphalan demonstrated increased cytotoxicity in a panel of sarcoma cell lines. The effects were mediated through activation of the intrinsic apoptotic pathway. In vivo, combinations of radiation, oncolytic virotherapy and standard ILP resulted in delayed tumour growth and prolonged survival when compared with standard ILP alone. However, local disease control could only be secured when such treatment was combined with surgical resection, the timing of which was crucial in determining outcome. Combinations of oncolytic virotherapy with surgical resection and radiation have direct clinical relevance in extremity sarcoma and represent an exciting prospect for improving outcomes in this pathology."
Alpha terpineol (See 2 studies directly below!)
- found in eucalyptus, lime, tea tree oils (https://tisserandinstitute.org/learn-more/alpha-terpineol/)
- also in apples, blueberries and limes in very small amounts
Alpha-Terpineol as Antitumor Candidate in Pre-Clinical Studies
https://pubmed.ncbi.nlm.nih.gov/33397274/
"Our data indicate that alpha-terpineol has antitumor activity revealed by cytogenetic mechanisms and / or loss of cell membrane integrity."
α-Terpineol reduces cancer pain via modulation of oxidative stress and inhibition of iNOS
https://pubmed.ncbi.nlm.nih.gov/29902764/
"These data provide strong evidence that TP may be an interesting candidate for the development of new safe analgesic drugs that are effective for cancer pain control."
Anticancer activity of an essential oil from Cymbopogon flexuosus (Lemongrass)
https://pubmed.ncbi.nlm.nih.gov/19121295/
"Intra-peritoneal administration of the oil significantly inhibited both ascitic and solid forms of Ehrlich and Sarcoma-180 tumors in a dose-dependent manner."
In vitro and in vivo antitumor effects of the essential oil from the leaves of Guatteria friesiana
https://pubmed.ncbi.nlm.nih.gov/22274812/
"Based on these results, we can conclude that EOGF possesses significant antitumor activity and has only low systemic toxicity. These effects could be assigned to its components α-, β-, and γ-eudesmol."
Squamous Cell Carcinoma
Phenformin Promotes Keratinocyte Differentiation via the calcineurin/NFAT Pathway
https://pubmed.ncbi.nlm.nih.gov/32619504/
"Taken together, our study reveals an anti-tumor activity of phenformin to promote keratinocyte differentiation that warrants future translational efforts to repurpose phenformin for the treatment of cutaneous squamous cell carcinomas."